Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

二价 mRNA-1273.214 疫苗对 SARS-CoV-2 omicron XBB* 感染的有效性

阅读：1
作者：Chemaitelly,Hiam,Ayoub,Houssein H,AlMukdad,Sawsan,Faust,Jeremy S,Tang,Patrick,Coyle,Peter,Yassine,Hadi M,Al Thani,Asmaa A,Al-Khatib,Hebah A,Hasan,Mohammad R,Al-Kanaani,Zaina,Al-Kuwari,Einas,Jeremijenko,Andrew,Kaleeckal,Anvar H,Latif,Ali N,Shaik,Riyazuddin M,Abdul-Rahim,Hanan F,Nasrallah,Gheyath K,Al-Kuwari,Mohamed G,Butt,Adeel A,Al-Romaihi,Hamad E,Al-Thani,Mohamed H,Al-Khal,Abdullatif,Bertollini,Roberto,Abu-Raddad,Laith J
期刊：Journal of Travel Medicine影响因子：6.400
时间：2023起止号：2023 Sep 5;30(5)
doi：10.1093/jtm/taad106

Abstract

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune imprinting effects, or both, may explain findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。